QuantiFERON-TB Gold In-Tube Test for Tuberculosis Prevention in HIV-Infected Patients
-
- Khawcharoenporn Thana
- Division of Infectious Diseases, Faculty of Medicine, Thammasat University
-
- Phetsuksiri Benjawan
- National Institute of Health, Department of Medical Sciences, Ministry of Public Health
-
- Rudeeaneksin Janisara
- National Institute of Health, Department of Medical Sciences, Ministry of Public Health
-
- Srisungngam Sopa
- National Institute of Health, Department of Medical Sciences, Ministry of Public Health
-
- Apisarnthanarak Anucha
- Division of Infectious Diseases, Faculty of Medicine, Thammasat University
この論文をさがす
抄録
<p>Optimal testing strategies for diagnosing latent tuberculosis infection and the administration of isoniazid preventive therapy (IPT) remain uncertain among human immunodeficiency virus (HIV)-infected patients. A 4-year prospective study was conducted among Thai HIV-infected patients who underwent simultaneous tuberculin skin test (TST) and QuantiFERON-TB Gold In-Tube Test (QFT-IT) at care entry. Based on baseline test results, patients were categorized into the following 4 groups: i) QFT-IT-positive, TST-reactive; ii) QFT-IT-positive, TST-non-reactive; iii) QFT-IT-negative, TST-reactive; and iv) QFT-IT-negative, TST-non-reactive. The QFT-IT-positive patients were offered 9-month IPT and were QFT-IT tested annually. Of the 150 enrolled patients, 8, 12, 16, and 114 patients were assigned to groups 1, 2, 3, and 4, respectively. Sixteen of 19 QFT-IT-positive patients (84%) completed IPT. The incidence of tuberculosis was significantly higher in patients who declined IPT than in those underwent treatment (11.11 vs. 0 case/100 patient-year; P < 0.001). Among the 16 patients completing IPT, 11 (69%) and 2 (12%) had QFT-IT reversion at 1 and 2 years after IPT, respectively. The remaining 3 (19%) did not demonstrate any reversion, and their baseline interferon-γ (IFN-γ) levels were above 1.2 IU/mL. Initial QFT-IT-guided IPT was effective in preventing tuberculosis. Serial QFT-IT for evaluating IPT effectiveness had limitations because of delayed or lack of reversion, especially for patients with high baseline IFN-γ levels.</p>
収録刊行物
-
- Japanese Journal of Infectious Diseases
-
Japanese Journal of Infectious Diseases 70 (5), 502-506, 2017
国立感染症研究所 Japanese Journal of Infectious Diseases 編集委員会
- Tweet
キーワード
詳細情報 詳細情報について
-
- CRID
- 1390282681218856960
-
- NII論文ID
- 130006096733
-
- NII書誌ID
- AA1132885X
-
- ISSN
- 18842836
- 13446304
-
- NDL書誌ID
- 028534797
-
- PubMed
- 28367883
-
- 本文言語コード
- en
-
- データソース種別
-
- JaLC
- NDL
- Crossref
- PubMed
- CiNii Articles
-
- 抄録ライセンスフラグ
- 使用不可